No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

byKathleen Lau

January 14, 2021

in StudyGraphics

RELATED REPORTS

2 Minute Medicine: Pharma Roundup- Obesity RNA deal, at-home Alzheimer’s dosing, oncology royalty financing, and first Bruton’s Tyrosine Kinase Inhibitor for Immune Thrombocytopenia [September 3, 2025]

Moderate to severe TBI is associated with elevated malignant brain tumor risk

2 Minute Medicine Rewind September 1, 2025

#VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma

RelatedReports

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Cardiology

2 Minute Medicine: Pharma Roundup- Obesity RNA deal, at-home Alzheimer’s dosing, oncology royalty financing, and first Bruton’s Tyrosine Kinase Inhibitor for Immune Thrombocytopenia [September 3, 2025]

September 3, 2025

Brain lesions on MRI linked with subsequent increased stroke risk

Neurology

Moderate to severe TBI is associated with elevated malignant brain tumor risk

September 1, 2025

Imatinib safe and effective as long-term treatment for chronic myeloid leukemia: The IRIS trial

Weekly Rewinds

2 Minute Medicine Rewind September 1, 2025

September 1, 2025

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence

Endocrinology

Switching to camizestrant after ESR1 mutation detection prolongs progression free survival in advanced breast cancer

August 28, 2025

Prescription of antibiotics for acute respiratory infections increasing

Common hospital complications associated with COVID-19 identified in a retrospective cohort study

Novel coronavirus identified from patients with pneumonia in Wuhan, China

O and Rh– blood groups may be associated with decreased risk for SARS-CoV-2 infection

#VisualAbstract AMLSG 09-09: Adding getuzumab ozogamicin (GO) to intensive therapy for Nucleophosmin1 mutated acute myeloid leukemia (NPM1mut AML) leads to better NPM1mut transcript clearance and a lower replase rate

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result